Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3 Completed 316 enrolled Vanda Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Timeline

Start: 2023-09-09
Primary completion: 2024-04-06
Completion: 2024-04-24

Outcome

Met primary endpoint

paper 10.4% of the 170-mg tradipitant group and 18.3% of the 85-mg tradipitant group experienced vomiting, compared with 37.7% of the placebo group PMID 42150111 ↗

paper P = 0.00002 and P = 0.0014, respectively PMID 42150111 ↗

Publications

Nguyen T, Willett KC, Daly LR, Junker J, Andreescu O, Dima L. Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness. Am J Ther. 2026 Jul-Aug 01;33(4):e324-e328. doi: 10.1097/MJT.0000000000002147. Epub 2026 May 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tradipitant	Small molecule	85 mg	Oral
Subject	Tradipitant	Small molecule	170 mg	Oral